Cargando…

Evaluation of a New Mordant Based Haematoxylin Dye (Haematoxylin X) for Use in Clinical Pathology

Recently, St John’s Dermatopathology Laboratory and CellPath Ltd have developed a new patented haematoxylin dye (Haematoxylin X) that utilises a chromium-based mordant (Chromium Sulphate). In this study, the performance of this new haematoxylin (Haematoxylin X) was compared against some commonly uti...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabriel, J. A., D’Amico, C., Kosgodage, U., Satoc, J., Haine, N., Willis, S., Orchard, G. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560741/
https://www.ncbi.nlm.nih.gov/pubmed/37818105
http://dx.doi.org/10.3389/bjbs.2023.11591
_version_ 1785117787640823808
author Gabriel, J. A.
D’Amico, C.
Kosgodage, U.
Satoc, J.
Haine, N.
Willis, S.
Orchard, G. E.
author_facet Gabriel, J. A.
D’Amico, C.
Kosgodage, U.
Satoc, J.
Haine, N.
Willis, S.
Orchard, G. E.
author_sort Gabriel, J. A.
collection PubMed
description Recently, St John’s Dermatopathology Laboratory and CellPath Ltd have developed a new patented haematoxylin dye (Haematoxylin X) that utilises a chromium-based mordant (Chromium Sulphate). In this study, the performance of this new haematoxylin (Haematoxylin X) was compared against some commonly utilised alum-based haematoxylins (Carazzi’s, Harris’ and Mayer’s) when used as a part of formalin-fixed paraffin embedded (FFPE) tissue, special stains, immunohistochemical counterstaining and frozen section (Mohs procedure) staining procedures. FFPE sections of different tissue types and frozen skin tissues were sectioned and stained with each haematoxylin subtype to allow for a direct comparison of staining quality. The slides were independently evaluated microscopically by two assessors. A combined score was generated to determine the sensitivity (defined as the intensity of haematoxylin staining being too weak or too strong and the colour of the haematoxylin staining not being blue/black) and specificity (defined as the presence of haematoxylin background staining, uneven staining, and staining deposits) for each of the four haematoxylin subtypes. The scoring criteria were based on the UKNEQAS Cellular pathology techniques assessment criteria. In FFPE tissue, the results for specificity identified Harris haematoxylin scoring the highest (91.2%) followed by Haematoxylin X (88.0%) and Mayer’s (87.0%). The sensitivity scores again identified Harris haematoxylin as scoring the highest (95.1%) followed by Haematoxylin X (90.0%) and Mayer’s (88.0%). In frozen tissue, the results for specificity identified Haematoxylin X as scoring the highest (85.5%) followed by Carazzi’s (80.7%) and Harris’ (77.4%). The sensitivity scores again identified Haematoxylin X as scoring the highest (86.8%) followed by Carazzi’s (82.0%) and Harris’ (81.0%). The results achieved with all four haematoxylins showed a high degree of comparability, with Harris’ haematoxylin scoring high scores overall compared to the other four when assessing FFPE sections. This may have been due to familiarity with the use of Harris’ haematoxylin in-house. There was also evidence of more pronounced staining of extracellular mucin proteins with Haematoxylin X compared to the other alum haematoxylins that were assessed. Haematoxylin X scored highest when used in frozen section staining. In addition, Haematoxylin X has a potential applications for use in IHC and special stains procedures as a counterstain.
format Online
Article
Text
id pubmed-10560741
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105607412023-10-10 Evaluation of a New Mordant Based Haematoxylin Dye (Haematoxylin X) for Use in Clinical Pathology Gabriel, J. A. D’Amico, C. Kosgodage, U. Satoc, J. Haine, N. Willis, S. Orchard, G. E. Br J Biomed Sci Health Archive Recently, St John’s Dermatopathology Laboratory and CellPath Ltd have developed a new patented haematoxylin dye (Haematoxylin X) that utilises a chromium-based mordant (Chromium Sulphate). In this study, the performance of this new haematoxylin (Haematoxylin X) was compared against some commonly utilised alum-based haematoxylins (Carazzi’s, Harris’ and Mayer’s) when used as a part of formalin-fixed paraffin embedded (FFPE) tissue, special stains, immunohistochemical counterstaining and frozen section (Mohs procedure) staining procedures. FFPE sections of different tissue types and frozen skin tissues were sectioned and stained with each haematoxylin subtype to allow for a direct comparison of staining quality. The slides were independently evaluated microscopically by two assessors. A combined score was generated to determine the sensitivity (defined as the intensity of haematoxylin staining being too weak or too strong and the colour of the haematoxylin staining not being blue/black) and specificity (defined as the presence of haematoxylin background staining, uneven staining, and staining deposits) for each of the four haematoxylin subtypes. The scoring criteria were based on the UKNEQAS Cellular pathology techniques assessment criteria. In FFPE tissue, the results for specificity identified Harris haematoxylin scoring the highest (91.2%) followed by Haematoxylin X (88.0%) and Mayer’s (87.0%). The sensitivity scores again identified Harris haematoxylin as scoring the highest (95.1%) followed by Haematoxylin X (90.0%) and Mayer’s (88.0%). In frozen tissue, the results for specificity identified Haematoxylin X as scoring the highest (85.5%) followed by Carazzi’s (80.7%) and Harris’ (77.4%). The sensitivity scores again identified Haematoxylin X as scoring the highest (86.8%) followed by Carazzi’s (82.0%) and Harris’ (81.0%). The results achieved with all four haematoxylins showed a high degree of comparability, with Harris’ haematoxylin scoring high scores overall compared to the other four when assessing FFPE sections. This may have been due to familiarity with the use of Harris’ haematoxylin in-house. There was also evidence of more pronounced staining of extracellular mucin proteins with Haematoxylin X compared to the other alum haematoxylins that were assessed. Haematoxylin X scored highest when used in frozen section staining. In addition, Haematoxylin X has a potential applications for use in IHC and special stains procedures as a counterstain. Frontiers Media S.A. 2023-09-25 /pmc/articles/PMC10560741/ /pubmed/37818105 http://dx.doi.org/10.3389/bjbs.2023.11591 Text en Copyright © 2023 Gabriel, D’Amico, Kosgodage, Satoc, Haine, Willis and Orchard. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Gabriel, J. A.
D’Amico, C.
Kosgodage, U.
Satoc, J.
Haine, N.
Willis, S.
Orchard, G. E.
Evaluation of a New Mordant Based Haematoxylin Dye (Haematoxylin X) for Use in Clinical Pathology
title Evaluation of a New Mordant Based Haematoxylin Dye (Haematoxylin X) for Use in Clinical Pathology
title_full Evaluation of a New Mordant Based Haematoxylin Dye (Haematoxylin X) for Use in Clinical Pathology
title_fullStr Evaluation of a New Mordant Based Haematoxylin Dye (Haematoxylin X) for Use in Clinical Pathology
title_full_unstemmed Evaluation of a New Mordant Based Haematoxylin Dye (Haematoxylin X) for Use in Clinical Pathology
title_short Evaluation of a New Mordant Based Haematoxylin Dye (Haematoxylin X) for Use in Clinical Pathology
title_sort evaluation of a new mordant based haematoxylin dye (haematoxylin x) for use in clinical pathology
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560741/
https://www.ncbi.nlm.nih.gov/pubmed/37818105
http://dx.doi.org/10.3389/bjbs.2023.11591
work_keys_str_mv AT gabrielja evaluationofanewmordantbasedhaematoxylindyehaematoxylinxforuseinclinicalpathology
AT damicoc evaluationofanewmordantbasedhaematoxylindyehaematoxylinxforuseinclinicalpathology
AT kosgodageu evaluationofanewmordantbasedhaematoxylindyehaematoxylinxforuseinclinicalpathology
AT satocj evaluationofanewmordantbasedhaematoxylindyehaematoxylinxforuseinclinicalpathology
AT hainen evaluationofanewmordantbasedhaematoxylindyehaematoxylinxforuseinclinicalpathology
AT williss evaluationofanewmordantbasedhaematoxylindyehaematoxylinxforuseinclinicalpathology
AT orchardge evaluationofanewmordantbasedhaematoxylindyehaematoxylinxforuseinclinicalpathology